{"changes":[],"country":"FR","description":"Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment, with lead candidate AP-01 (TAX2) blocking TSP-1 binding to CD47. The Reims-based biotech serves patients with glioblastoma, ovarian, colorectal, and pancreatic cancer. Its peptide approach offers an alternative to other CD47 blockers while modulating.","domain":"apmonia-therapeutics.com","employees":null,"founded":2019,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"biotech","investors":[],"lat":49.257789,"lng":4.031926,"location":"Reims, France","name":"Apmonia Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":2700000,"currency":"EUR","date":"2024-09-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-02","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"apmonia-therapeutics-com","sources":[{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-02","status":"attributed","url":null},{"fact":"existence","publisher":"apmonia-therapeutics.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://apmonia-therapeutics.com"},{"fact":"description","publisher":"apmonia-therapeutics.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://apmonia-therapeutics.com"}],"stage":null,"techStack":["PHP 8.4","WordPress 6.9.4","Twenty Seventeen","Yoast SEO 27.6","Google Analytics","Google Tag Manager","jQuery Migrate 3.4.1","imagesLoaded 5.0.0","Elementor 4.0.8","DoubleClick Floodlight","Contact Form 7 6.1.6","CookieYes 3.4.2"],"totalRaisedUsd":7620000,"updatedAt":"2026-05-02"}